Burkart F, Baitsch G, Braun S, Bertel O, Cocco G
Cardiology. 1982;69 Suppl:165-71. doi: 10.1159/000173551.
57 patients were admitted to the study, 3-6 weeks after acute myocardial infarction. They received either placebo or 1 mg/kg tiapamil intravenously according to a randomized, double-blind procedure. The study had two objectives: (a) to assess the effect of tiapamil on work tolerance and exercise-induced myocardial ischemia: (b) to demonstrate possible antiarrhythmic effects against exercise-induced arrhythmias. The duration of exercise and physical work capacity increased slightly in both groups, these effects, however, not reaching statistical significance. On the other hand, the number of exercise-induced extrasystoles did not change significantly under placebo but decreased from 30.9 to 14.8 beats/min after tiapamil (p less than 0.01). No side effects were observed. While the hemodynamic effects of tiapamil in patients with coronary artery disease are yet to be elucidated, our findings confirm the efficacy of this calcium antagonist against exercise-induced ventricular premature beats in patients with coronary artery disease.
57例患者在急性心肌梗死后3至6周入选本研究。根据随机双盲程序，他们接受了安慰剂或1mg/kg替帕米静脉注射。该研究有两个目的：(a)评估替帕米对工作耐力和运动诱发心肌缺血的影响；(b)证明对运动诱发心律失常可能的抗心律失常作用。两组的运动持续时间和体力工作能力均略有增加，但这些影响未达到统计学意义。另一方面，运动诱发的期前收缩数量在安慰剂组无显著变化，但在替帕米治疗后从30.9次/分钟降至14.8次/分钟(p<0.01)。未观察到副作用。虽然替帕米在冠心病患者中的血流动力学效应尚待阐明，但我们的研究结果证实了这种钙拮抗剂对冠心病患者运动诱发室性早搏的疗效。
